Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:26:43.713Z.
Consensus retrieved: 2026-10-06T12:26:07.273Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:26:43.713Z.
Quote observation: 2026-10-06T19:24:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 767633254d5919bd59cda52a5696942c7bb29bc9076435c5b91744fa0c767718
Forward PE Ratio (N/A) = Dated Quote Price ($0.93) / Consensus Forward EPS ($-0.89)
FORWARD PE RATIO
N/A
Werewolf Therapeutics, Inc.
Market Cap
$45.07M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | $45.07M | N/A |
| DarioHealth Corp. (DRIO)vs › | $45.05M | N/A |
| SANUWAVE Health Inc. (SNWV)vs › | $44.89M | N/A |
| Celularity Inc. (CELU)vs › | $45.88M | N/A |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $43.63M | N/A |
| Nano-X Imaging Ltd. (NNOX)vs › | $42.81M | N/A |
| Instil Bio, Inc. (TIL)vs › | $47.41M | N/A |
| CVRx, Inc. (CVRX)vs › | $42.72M | N/A |
| Lite Strategy, Inc. (LITS)vs › | $47.47M | N/A |
| BioStem Technologies, Inc. (BSEM)vs › | $42.46M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.93, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.89 | $-0.89 – $-0.89 | 1 | n/m |
| 2027-12-31 | $-0.59 | $-0.59 – $-0.59 | 1 | n/m |
| 2028-12-31 | $-1.47 | $-1.47 – $-1.47 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
